Xtant Medical (XTNT) Set to Announce Quarterly Earnings on Tuesday

Xtant Medical (NYSEAMERICAN:XTNT) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.0250) per share and revenue of $25.48 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings data on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.05). Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%. The company had revenue of $23.03 million for the quarter, compared to analyst estimates of $24.88 million.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT traded up $0.01 during trading on Tuesday, reaching $0.28. 24,828 shares of the stock were exchanged, compared to its average volume of 610,924. The firm has a market cap of $39.95 million, a PE ratio of -3.56 and a beta of -0.20. The company has a current ratio of 2.16, a quick ratio of 1.05 and a debt-to-equity ratio of 0.18. Xtant Medical has a 12 month low of $0.27 and a 12 month high of $0.85. The stock has a 50-day moving average price of $0.33 and a 200-day moving average price of $0.46.

Analyst Ratings Changes

Separately, Loop Capital set a $1.00 price target on Xtant Medical in a research note on Wednesday, September 2nd. Two analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $1.00.

About Xtant Medical

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and distributing orthobiologic and spinal implant products. Its offerings are designed to support bone growth, spinal fusion and the repair or reconstruction of musculoskeletal tissue.

The company’s product portfolio includes biologic materials such as allograft and other regenerative tissue products, along with spinal implants, interbody devices, fixation systems and related surgical instruments.